High Circulating Plasma Soluble Receptor for Advanced Glycation End-Products in Early COVID-19-associated Acute Respiratory Distress Syndrome: Pathophysiological Significance?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

1. Oxidative stress and COVID-19-associated neuronal dysfunction: mechanisms and therapeutic implications.Acta biochimica et biophysica Sinica · 2023
   Review

Corrections and comments

• Commented on by
  Reply to Jain: High Circulating Plasma Soluble Receptor for Advanced Glycation End-Products in Early COVID-19-associated Acute Respiratory Distress Syndrome: Pathophysiological Significance?2022
• Comment on
  Importance of Lung Epithelial Injury in COVID-19-associated Acute Respiratory Distress Syndrome: Value of Plasma Soluble Receptor for Advanced Glycation End-Products.2021

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as